|
Houston Technology Center
|
713.658.1750 
|
Oncolix, Inc.
Oncolix is a biotechnology company that is developing Prolanta for ovarian and breast cancer. Prolanta is a first-in-class prolactin receptor antagonist that induces apoptosis of cancerous cells. The drug also has anti-HER2 activity. Prolanta is currently in late preclinical studies (non-human primates) and is expected to be evaluated in human clinical trials in early 2011.
